Fig. 7
From: INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer
A Western blot showing effects of treatment of 21-MT1 cells with 10 ng/ml recombinant Activin or siRNA against INHBA. Activin treatment activates p-SMAD2 in 21-MT1 cells. Knockdown of INHBA has minimal impact on the p-SMAD2 levels compared to baseline conditions. B Growth curves for 21-MT1 cells treated with different types of recombinant Activin or Inhibin. Cells were treated with siRNA against INHBA then 50 ng/ml recombinant protein was added to the siRNA-treated cells and growth was assessed for 144 h. No Activin+ siRNA-treated cells showed any significant growth rescue compared to siRNA alone treated cells. Error bars are ± S.D. C Growth curves for 21-MT1 cells treated with scramble control siRNA or INHBA siRNA plus 10 or 20 ng/ml of an siRNA-resistant INHBA cDNA plasmid. Addition of 10 or 20 ng/ml plasmid results in significant rescue of the growth inhibition caused by INHBA knockdown (p < 0.001). Error bars are ± S.D